

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 May 2001 (31.05.2001)

PCT

(10) International Publication Number
WO 01/37835 A1

(51) International Patent Classification⁷: A61K 31/4439, 31/506, C07D 401/04, 403/04

(74) Agents: DINNER, Dara, L. et al.; SmithKline Beecham Corporation, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).

(21) International Application Number: PCT/US00/31791

(22) International Filing Date:
20 November 2000 (20.11.2000)

(81) Designated States (*national*): AE, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CZ, DZ, EE, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, TZ, UA, US, UZ, VN, YU, ZA.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/166,886 22 November 1999 (22.11.1999) US
60/166,885 22 November 1999 (22.11.1999) US
60/166,814 22 November 1999 (22.11.1999) US
60/166,895 22 November 1999 (22.11.1999) US

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*):
SMITHKLINE BEECHAM PLC. [US/US]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): ADAMS, Jerry, L. [US/US]; 611 Forest Road, Wayne, PA 19087 (US). JOHNSON, Neil, W. [US/US]; 525 Rock Raymond Road, Downingtown, PA 19335 (US). MURRAY, Jeffrey, H. [US/US]; 2106 Harrison Court, Norristown, PA 19403 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/37835 A1

(54) Title: NOVEL COMPOUNDS

(57) Abstract: The present invention is directed to novel compounds of Formula (I) for use in the treatment of diseases, in a mammal, in which inappropriate, excessive or undesirable angiogenesis has occurred and/or where excessive Tie2 receptor activity has occurred.

NOVEL COMPOUNDS

5

FIELD OF THE INVENTION

The present invention relates to the treatment of diseases, in a mammal, in which inappropriate, excessive or undesirable angiogenesis has occurred and/or where excessive Tie2 receptor activity has occurred.

10

BACKGROUND OF THE INVENTION

Chronic proliferative diseases are often accompanied by profound angiogenesis, which can contribute to or maintain an inflammatory and/or proliferative state, or which leads to tissue destruction through the invasive proliferation of blood vessels. (Folkman, *EXS* 79:1-8, 1997; Folkman, *Nature Medicine* 1:27-31, 1995; Folkman and Shing, *J. Biol. Chem.* 267:10931, 1992).

Angiogenesis is generally used to describe the development of new or replacement blood vessels, or neovascularisation. It is a necessary and physiological normal process by which the vasculature is established in the embryo. Angiogenesis does not occur, in general, in most normal adult tissues, exceptions being sites of ovulation, menses and wound healing. Many diseases, however, are characterized by persistent and unregulated angiogenesis. For instance, in arthritis, new capillary blood vessels invade the joint and destroy cartilage (Colville-Nash and Scott, *Ann. Rheum. Dis.*, 51, 919, 1992). In diabetes (and in many different eye diseases), new vessels invade the macula or retina or other ocular structures, and may cause blindness (Brooks et al., *Cell*, 79, 1157, 1994). The process of atherosclerosis has been linked to angiogenesis (Kahlon et al., *Can. J. Cardiol.* 8, 60, 1992). Tumor growth and metastasis have been found to be angiogenesis-dependent (Folkman, *Cancer Biol.* 3, 65, 1992; Denekamp, *Br. J. Rad.* 66, 181, 1993; Fidler and Ellis, *Cell*, 79, 185, 1994).

The recognition of the involvement of angiogenesis in major diseases has been accompanied by research to identify and develop inhibitors of angiogenesis. These inhibitors are generally classified in response to discrete targets in the angiogenesis cascade, such as activation of endothelial cells by an angiogenic signal; synthesis and release of degradative enzymes; endothelial cell migration; proliferation of endothelial cells; and formation of capillary tubules. Therefore,

angiogenesis occurs in many stages and attempts are underway to discover and develop compounds that work to block angiogenesis at these various stages.

There are publications that teach that inhibitors of angiogenesis, working by diverse mechanisms, are beneficial in diseases such as cancer and metastasis (O'Reilly et al., *Cell*, 79, 315, 1994; Ingber et al., *Nature*, 348, 555, 1990), ocular diseases (Friedlander et al., *Science*, 270, 1500, 1995), arthritis (Peacock et al., *J. Exp. Med.* 175, 1135, 1992; Peacock et al., *Cell. Immun.* 160, 178, 1995) and hemangioma (Taraboletti et al., *J. Natl. Cancer Inst.* 87, 293, 1995).

Angiogenesis signals result from the interaction of specific ligands with their receptors. The Tie1 and Tie2 receptors are single-transmembrane, tyrosine kinase receptors (Tie stands for Tyrosine kinase receptors with immunoglobulin and EGF homology domains). Both were recently cloned and reported by several groups (Dumont et al., *Oncogene* 8:1293-1301, 1993; Partanen et al., *Mol. Cell Biol.* 12:1698-1707, 1992; Sato et al., *Proc. Natl. Acad. Sci. USA* 90:9355-9358, 1993).

Based upon the importance of Tie2 receptors in angiogenesis, inhibition of Tie2 kinase activity is predicted to interrupt angiogenesis, providing disease-specific therapeutic effects. Recently, Lin et al. (*J. Clin. Invest.* 100:2072-2078, 1997) has shown that exogenously administered soluble Tie2 receptor inhibited angiogenesis and cancer growth in animal models. Thus inhibition of Tie2 receptors by other means, such as inhibition of Tie2 receptor kinase activity, is expected to have therapeutic benefit in proliferative diseases involving angiogenesis.


The current application teaches the novel finding that compounds of specific structure can inhibit the kinase activity of the Tie2 receptor, block its signal transduction and thus may be beneficial for proliferative diseases via inhibition of signals for angiogenesis.

SUMMARY OF THE INVENTION

The present invention is directed to novel compounds of Formula (I), and pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutically acceptable diluent or carrier.

Another aspect of the present invention is the use of compounds of Formula (I) as Tie2 receptor kinase inhibitors. Tie2 receptor kinase inhibitors may be used in the treatment, including prophylaxis, of inhibition of angiogenesis, or chronic inflammatory or proliferative or angiogenic diseases or disorders which are caused by excessive or inappropriate angiogenesis in a mammal in need thereof.

The novel compounds of Formula (I) are represented by the structure:



(I)

5 wherein

V is CH or N;

Ar is a naphth-2-yl, naphth-1-yl, a bicyclic or a tricyclic heteroaromatic ring, which rings may be optionally substituted;

Y is $\text{NR}^{10}\text{R}^{11}$, $\text{NR}^{10}\text{C}(\text{Z})\text{NR}^{10}\text{R}^{11}$, $\text{NR}^{10}\text{C}(\text{Z})\text{NR}^{10}\text{C}(\text{Z})\text{OR}^{11}$, $\text{NR}^{10}\text{COOR}^{11}$ or
 10 $\text{NR}^{10}\text{SO}_2\text{R}^{11}$;

n is 0, 1, 2, 3 or 4;

X is O, CH_2 , S or NH;

Z is oxygen or sulfur;

R^1 is independently hydrogen, X-R^4 , halogen, hydroxy, optionally substituted
 15 C_{1-6} alkyl, optionally substituted C_{1-6} alkylsulfinyl, CH_2OR^5 , amino, mono or di-
 C_{1-6} alkylamino, $\text{N}(\text{R}^6)\text{C}(\text{O})\text{R}^7$, $\text{N}(\text{R}^6)\text{S}(\text{O})_2\text{R}^8$, or a 5 to 7-membered N-heterocyclyl
 ring which optionally contains an additional heteroatom selected from O, S and NR^9 ;

R^2 and R^3 independently represent optionally substituted C_{1-6} alkyl, or R^2
 and R^3 together with the carbon atom to which they are attached form an
 20 optionally substituted C_{3-7} cycloalkyl or C_{5-7} cycloalkenyl ring, or R^2 and R^3
 together with the carbon atom to which they are attached form an optionally
 substituted 5 to 7-membered heterocyclyl ring containing up to 3 heteroatoms
 selected from N, O and S;

R^4 is independently C_{1-6} alkyl, aryl, arylC_{1-6} alkyl, heterocyclyl,
 25 heterocyclyl C_{1-6} alkyl, heteroaryl, or a heteroaryl C_{1-6} alkyl moiety, and wherein any of
 these moieties may be optionally substituted;

R^5 is hydrogen, $\text{C}(\text{Z})\text{R}^{12}$ or optionally substituted C_{1-6} alkyl, optionally
 substituted aryl, optionally substituted arylC_{1-6} alkyl, or $\text{S}(\text{O})_2\text{R}^8$;

R^6 is hydrogen or C_{1-6} alkyl;

30 R^7 is hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, aryl, arylC_{1-6} alkyl, heteroaryl,
 heteroaryl C_{1-6} alkyl, heterocyclyl, or heterocyclyl C_{1-6} alkyl;

R^8 is C_{1-6} alkyl, C_{3-7} cycloalkyl, aryl, aryl C_{1-6} alkyl, heteroaryl, heteroaryl C_{1-6} alkyl, heterocyclyl, or heterocyclyl C_{1-6} alkyl;

R^9 is hydrogen, C_{1-4} alkyl, C_{3-7} cycloalkyl or aryl;

R^{10} and R^{12} are independently selected from hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl C_{1-6} alkyl, aryl, aryl C_{1-6} alkyl, heterocyclyl, heterocyclyl C_{1-6} alkyl, heteroaryl and heteroaryl C_{1-6} alkyl, any of which may be optionally substituted; and

R^{11} is hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl C_{1-6} alkyl, aryl, aryl C_{1-6} alkyl, heterocyclyl, heterocyclyl C_{1-6} alkyl, heteroaryl, or heteroaryl C_{1-6} alkyl, any of which may be optionally substituted; or R^{10} and R^{11} together with the nitrogen may form a 5 to 7 membered ring optionally containing an additional heteroatom selected from O, S, or NR^9 ;

or a pharmaceutically acceptable salt thereof.

15 DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to novel compounds which can inhibit Tie2 kinase, and use of these compounds for inhibition of angiogenesis in the treatment of chronic inflammatory or proliferative or angiogenic diseases which are caused by excessive or inappropriate angiogenesis in a mammal in need thereof.

20 In the compounds of formula (I), V is suitably CH or N, preferably carbon.

Suitably, the pyridyl or pyrimidine ring is optionally substituted, independently, one to two times independently by R^1 .

Suitably, R^1 is independently hydrogen, $X-R^4$, halogen, hydroxy, optionally substituted C_{1-6} alkyl, optionally substituted C_{1-6} alkylsulfinyl, CH_2OR^5 , amino, mono or di- C_{1-6} alkylamino, $N(R^6)C(O)R^7$, $N(R^6)S(O)_2R^8$, or a 5 to 7-membered N-heterocyclyl ring which optionally contains an additional heteroatom selected from O, S and NR^9 . Preferably, the pyridyl or pyrimidine is substituted in the 2-position. Preferably, R^1 is hydrogen or $X-R^4$.

X is suitably, O, CH_2 , S or NH. Preferably X is oxygen or nitrogen.

30 R^4 is independently C_{1-6} alkyl, aryl, aryl C_{1-6} alkyl, heterocyclyl, heterocyclyl C_{1-6} alkyl, heteroaryl, or a heteroaryl C_{1-6} alkyl moiety, and wherein any of these moieties may be optionally substituted. Preferably R^4 is an optionally substituted alkyl, aryl, or arylalkyl group.

When R^4 is aryl, it is preferably an optionally substituted phenyl. When R^4 is aryl alkyl, it is preferably an optionally substituted benzyl or phenethyl.

These R^4 moieties may be optionally substituted one or more times, preferably 1 to 3 times, independently with halogen; C_{1-4} alkyl, such as methyl, ethyl, propyl, isopropyl, or t-butyl; halosubstituted alkyl, such as CF_3 ; hydroxy; hydroxy substituted C_{1-4} alkyl; C_{1-4} alkoxy, such as methoxy or ethoxy;

5 $S(O)_m$ alkyl and $S(O)_m$ aryl (wherein m is 0, 1, or 2); $C(O)OR^{11}$, such as $C(O)C_{1-6}$ alkyl or $C(O)OH$ moieties; $C(O)R^{11}$; $OC(O)R^8$; $O-(CH_2)_s-O-$, such as in a ketal or dioxoalkylene bridge (s is a number having a value of 1 to 5); amino; mono- and di- C_{1-6} alkylsubstituted amino; $N(R^{10})C(O)R^7$; $C(O)NR^{10}R^{11}$; cyano, nitro, or an N-heterocyclyl ring which ring has from 5 to 7 members and optionally contains an

10 additional heteroatom selected from oxygen, sulfur or NR^9 ; optionally substituted aryl, such as phenyl; an optionally substituted arylalkyl, such as benzyl or phenethyl; aryloxy, such as phenoxy; or arylalkyloxy such as benzyloxy; these aryl and arylalkyl moieties may be substituted with halogen, alkyl, alkoxy, $S(O)_m$ alkyl, amino, or mono- and di- C_{1-6} alkylsubstituted amino.

15 Preferably the R^4 moieties are substituted with an amino, mono- or di- C_{1-6} alkylsubstituted amino, or an N-heterocyclyl ring which ring has from 5 to 7 members and optionally contains an additional heteroatom selected from oxygen, sulfur or NR^9 .

Suitably, R^2 and R^3 independently represent optionally substituted C_{1-6} alkyl, or R^2 and R^3 together with the carbon atom to which they are attached form

20 an optionally substituted C_{3-7} cycloalkyl or C_{5-7} cycloalkenyl ring, or R^2 and R^3 together with the carbon atom to which they are attached form an optionally substituted 5 to 7-membered heterocyclyl ring containing up to 3 heteroatoms selected from N, O and S. Preferably R^2 and R^3 independently represent

25 optionally substituted C_{1-6} alkyl.

Suitably, n is 0, 1, 2, 3 or 4. Preferably, n is 1.

Suitably, Y is $NR^{10}R^{11}$, $NR^{10}C(Z)NR^{10}R^{11}$, $NR^{10}C(Z)NR^{10}C(Z)OR^{11}$, $NR^{10}COOR^{11}$ or $NR^{10}SO_2R^{11}$.

Suitably, R^{11} is hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl C_{1-6} alkyl, aryl, aryl C_{1-6} alkyl, heterocyclyl, heterocyclyl C_{1-6} alkyl, heteroaryl, or heteroaryl C_{1-6} alkyl, any of

30 which may be optionally substituted; or R^{10} and R^{11} together with the nitrogen to which they are attached form a 5 to 7 membered heterocyclic ring optionally containing an additional heteroatom selected from O, S, or NR^9 .

While R^{11} is optionally substituted as defined in the specification, it is preferably,

35 an unsubstituted or substituted alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl C_{1-6} alkyl, heterocyclyl, heterocyclyl C_{1-6} alkyl, heteroaryl, or a heteroaryl C_{1-6} alkyl. The alkyl if substituted is

preferably substituted one or more times by halogen, such as in CF_3 , CH_2CF_3 , or $(\text{CH}_2)_2\text{Cl}$ or $(\text{CH}_2)_3\text{Cl}$, or by a C_{1-6} alkoxy, a C_{1-6} alkylthio, C_{1-6} alkyl sulphinyl or C_{1-6} alkyl sulphonyl group; if R^{11} is a C_{3-7} cycloalkyl C_{1-6} alkyl, it is preferably a 5 or 6 membered ring, such as cyclohexylmethyl; if R^{11} is a heterocyclyl C_{1-6} alkyl, it is preferably a morpholino

5 C_{1-6} alkyl, or a piperidine C_{1-6} alkyl; or if a heteroaryl C_{1-6} alkyl moiety, an optionally substituted isoxazolyl.

Suitably, R^{10} and R^{12} are independently selected from hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl C_{1-6} alkyl, heterocyclyl, heterocyclyl C_{1-6} alkyl, aryl, aryl C_{1-6} alkyl, heteroaryl or heteroaryl C_{1-6} alkyl, any of which may be optionally substituted.

10 The R^{10} group and R^{12} moieties may be optionally substituted as defined for the alkyl term.

Suitably, R^5 is hydrogen, $\text{C}(\text{Z})\text{R}^{12}$ or optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, or $\text{S}(\text{O})_2\text{R}^8$.

Suitably, R^6 is hydrogen or C_{1-6} alkyl.

Suitably, R^7 is hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, aryl, aryl C_{1-6} alkyl, heteroaryl, 15 heteroaryl C_{1-6} alkyl, heterocyclyl, or heterocyclyl C_{1-6} alkyl.

Suitably, R^8 is C_{1-6} alkyl, C_{3-7} cycloalkyl, aryl, aryl C_{1-6} alkyl, heteroaryl, heteroaryl C_{1-6} alkyl, heterocyclyl, or heterocyclyl C_{1-6} alkyl.

Suitably, R^9 is hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl or aryl.

Suitably, R^{10} and R^{12} are independently selected from hydrogen, C_{1-6} alkyl, 20 C_{3-7} cycloalkyl, heterocyclyl, heterocyclyl C_{1-6} alkyl, aryl, aryl C_{1-6} alkyl, heteroaryl or heteroaryl C_{1-6} alkyl, any of which may be optionally substituted.

Suitably, Z is oxygen or sulfur.

Suitably, Ar is a naph-2-yl, naph-1-yl, a bicyclic or a tricyclic heteroaromatic ring, which ring may be optionally substituted in any ring. A bicyclic 25 or tricyclic heteroaromatic ring system is a fused ring system that may include a carbocyclic ring. Examples of such ring systems include quinoline, isoquinoline, benzimidazole, benzothiophene or benzofuran, benzoxazole, benzthiazole, dibenzofuran, dibenzothiophene, benzthiodiazole, benztriazole, or indolyl.

The Ar ring may be optionally substituted one or more times, preferably 1 to 3 times, 30 independently, in any ring. Suitable substituents include halogen, C_{1-6} alkyl, aryl, aryl C_{1-6} alkyl, cycloalkyl, cycloalkyl C_{1-6} alkyl, C_{1-6} alkoxy C_{1-6} alkyl, halosubstituted C_{1-6} alkyl, aryl C_{1-6} alkoxy, $(\text{CR}^{13}\text{R}^{14})_t\text{OR}^{12}$, nitro, cyano, $(\text{CR}^{13}\text{R}^{14})_t\text{NR}^{10}\text{R}^{11}$, $(\text{CR}^{13}\text{R}^{14})_t\text{NR}^{10}\text{C}(\text{Z})\text{R}^{12}$, $(\text{CR}^{13}\text{R}^{14})_t\text{C}(\text{Z})\text{NR}^{10}\text{R}^{11}$, $(\text{CR}^{13}\text{R}^{14})_t\text{COR}^{12}$, $(\text{CR}^{13}\text{R}^{14})_t\text{ZC}(\text{Z})\text{R}^{12}$, $(\text{CR}^{13}\text{R}^{14})_t\text{C}(\text{Z})\text{OR}^{12}$, $(\text{CR}^{13}\text{R}^{14})_t\text{C}(\text{O})\text{NR}^{10}\text{R}^{11}$, 35 $(\text{CR}^{13}\text{R}^{14})_t\text{NR}^{10}\text{C}(\text{Z})\text{NR}^{10}\text{R}^{11}$, $(\text{CR}^{13}\text{R}^{14})_t\text{NR}^{10}\text{C}(=\text{NH})\text{NR}^{10}\text{R}^{11}$.

$(\text{CR}^{13}\text{R}^{14})_t\text{C}(=\text{NH})-\text{NR}^{10}\text{R}^{11}$, $(\text{CR}^{13}\text{R}^{14})_t\text{NR}^{10}\text{S}(\text{O})_2\text{R}^8$, $(\text{CR}^{13}\text{R}^{14})_t\text{S}(\text{O})_2\text{NR}^{10}\text{R}^{11}$,
 $(\text{CR}^{13}\text{R}^{14})_t\text{S}(\text{O})_m\text{R}^{12}$, heterocyclyl, heteroaryl, heterocyclyl C_{1-6} alkyl or heteroaryl C_{1-6} alkyl.

Suitably t is 0, or an integer having a value of 1 to 10. Preferably t is 0, or 1, more preferably 0.

5 Suitably, R^{13} and R^{14} are independently hydrogen, or a C_{1-6} alkyl.

Preferably, Ar is substituted one or more times by halo, cyano,

$(\text{CR}^{13}\text{R}^{14})_t\text{C}(\text{Z})\text{NR}^{10}\text{R}^{11}$, $(\text{CR}^{13}\text{R}^{14})_t\text{C}(\text{Z})\text{OR}^{12}$, $(\text{CR}^{13}\text{R}^{14})_t\text{COR}^{12}$, $(\text{CR}^{13}\text{R}^{14})_t\text{S}(\text{O})_m\text{R}^{12}$,
 $(\text{CR}^{13}\text{R}^{14})_t\text{OR}^{12}$, halo-substituted- C_{1-6} alkyl, C_{1-6} alkyl, $(\text{CR}^{13}\text{R}^{14})_t\text{NR}^{10}\text{C}(\text{Z})\text{R}^{12}$,
 $(\text{CR}^{13}\text{R}^{14})_t\text{NR}^{10}\text{S}(\text{O})_2\text{R}^8$, $(\text{CR}^{13}\text{R}^{14})_t\text{S}(\text{O})_2\text{NR}^{10}\text{R}^{11}$, $(\text{CR}^{13}\text{R}^{14})_t\text{ZC}(\text{Z})\text{R}^{12}$, or

10 $(\text{CR}^{13}\text{R}^{14})_t\text{NR}^{10}\text{R}^{11}$.

Preferably, the Ar ring is substituted one or more times by halo, hydroxy, C_{1-6} alkyl, halosubstituted C_{1-6} alkyl, hydroxy C_{1-6} alkyl, and C_{1-6} alkoxy. More preferred substitution is C_{1-6} alkoxy group, such as methoxy; a C_{1-6} alkyl, such as methyl, or halogen, such as fluorine or chlorine.

15 Preferably the Ar ring is a naphthyl ring, more preferably a naphth-2-yl ring. If Ar is a bicycloheteroaryl ring it is preferably a benzothiophene or a benzofuran ring. A preferred ring placement for the naphth-2-yl ring is in the 6-position.

For use herein, the term "alkyl", and "alkenyl" groups, individually or as part
 20 of a larger group e.g. "alkoxy", may be straight or branched chain radicals containing up to six carbon atoms, unless otherwise limited, including, but not limited to, methyl, ethyl, *n*-propyl, *iso*-propyl, *n*-butyl, *sec*-butyl, *iso*-butyl, *tert*-butyl, and the like. The alkyl and alkenyl groups may be optionally substituted as herein defined.

For use herein, "cycloalkyl" includes cyclic radicals having from three to eight
 25 ring carbon atoms, including but not limited to cyclopropyl, cyclopentyl, cyclohexyl, and the like. The cycloalkyl groups may be optionally substituted as herein defined.

For use herein, "cycloalkenyl" includes cyclic radicals, preferably of 5 to 8
 carbons, which have at least one bond including but not limited to cyclopentenyl, cyclohexenyl, and the like. The cycloalkenyl groups may be optionally substituted as
 30 herein defined.

For use herein the term "aryl" (on its own or in any combination, such as
 "arylalkyl" or "aryloxy") includes a single or fused ring system, suitably containing
 from 4 to 7, preferably 5 or 6 ring atoms in each ring, which rings, may each be
 unsubstituted or substituted by, independently for example, up to three substituents.

35 A fused ring system may include an aliphatic ring, such as a saturated or partially saturated ring, and need include only one aromatic ring. Suitable aryl groups

include phenyl and naphthyl such as 1-naphthyl or 2-naphthyl. The aryl rings may be optionally substituted as herein defined unless otherwise indicated.

For use herein the term "heterocyclyl" (on its own or in any combination, such as "heterocyclyl alkyl" or "heterocyclyl oxy") suitably includes, unless otherwise
 5 defined, non-aromatic, single and fused rings suitably containing up to four heteroatoms in each ring, each of which independently selected from O, N and S, and which rings, may be unsubstituted or substituted independently by, for example, up to three substituents. Each heterocyclic ring suitably has from 4 to 7, preferably 5 or 6, ring atoms. A fused heterocyclic ring system may include carbocyclic rings and
 10 need include only one heterocyclic ring. Examples of heterocyclyl groups include pyrrolidine, piperidine, piperazine, morpholine, imidazolidine and pyrazolidine. The heterocyclic and heterocyclic rings may be optionally substituted as herein defined, unless otherwise indicated.

When used herein, the term "heteroaryl" (on its own or in any combination,
 15 such as "heteroaryloxy" or "heteroarylalkyl") suitably includes, unless otherwise defined, mono- and bicyclic heteroaromatic ring systems comprising up to four, preferably 1 or 2, heteroatoms each selected from O, N and S. Each ring may have from 4 to 7, preferably 5 or 6, ring atoms. A bicyclic heteroaromatic ring system may include a carbocyclic ring. Examples of heteroaryl groups include pyrrole,
 20 quinoline, isoquinoline, pyridine, pyrimidine, oxazole, thiazole, thiadiazole, triazole, imidazole, benzimidazole, isoxazole, thiophene, benzothiophene, furan and benzofuran. The heteroaryl rings may be optionally substituted as defined herein unless otherwise indicated.

Suitably the when the term "optionally substituted" is used herein, such as on
 25 the alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, heterocyclyl, heterocyclalkyl, heteroaryl, and heteroarylalkyl groups, unless otherwise defined, shall mean that the group may be optionally substituted one or more times, preferably by one to three substituents, each independently selected from halogen, C₁₋₆alkyl, aryl, arylC₁₋₆alkyl, cycloalkyl, cycloalkyl C₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkyl,
 30 halosubstituted C₁₋₆alkyl, arylC₁₋₆alkoxy, (CR¹³R¹⁴)_tOR¹², nitro, cyano, (CR¹³R¹⁴)_tNR¹⁰R¹¹, (CR¹³R¹⁴)_tNR¹⁰C(Z)R¹², (CR¹³R¹⁴)_tC(Z)NR¹⁰R¹¹, (CR¹³R¹⁴)_tCOR¹², (CR¹³R¹⁴)_tZC(Z)R¹², (CR¹³R¹⁴)_tC(Z)OR¹², (CR¹³R¹⁴)_tC(O)NR¹⁰R¹¹, (CR¹³R¹⁴)_tNR¹⁰C(Z)NR¹⁰R¹¹, (CR¹³R¹⁴)_tNR¹⁰C(=NH)NR¹⁰R¹¹, (CR¹³R¹⁴)_tC(=NH)-NR¹⁰R¹¹,
 35 (CR¹³R¹⁴)_tNR¹⁰S(O)₂R⁸, (CR¹³R¹⁴)_tS(O)₂NR¹⁰R¹¹, S(O)_mR¹², heterocyclyl,

heteroaryl, heterocyclylC₁₋₆alkyl or heteroaryl C₁₋₆alkyl. In addition, two adjacent ring carbon atoms may be linked to form a bicyclic system.

Particular compounds according to the invention include those mentioned in
5 the examples and their pharmaceutically acceptable salts.

It will be appreciated that for use in medicine the salts of the compounds of formula (I) should be pharmaceutically acceptable. Suitable pharmaceutically acceptable salts will be apparent to those skilled in the art and include those described in *J. Pharm. Sci.*, 1977, **66**, 1-19, such as acid addition salts formed with
10 inorganic acids e.g. hydrochloric, hydrobromic, sulphuric, nitric or phosphoric acid; and organic acids e.g. succinic, maleic, acetic, fumaric, citric, tartaric, benzoic, p-toluenesulfonic, methanesulfonic or naphthalenesulfonic acid. Other salts e.g. oxalates, may be used, for example in the isolation of compounds of formula (I) and are included within the scope of this invention.

15 The compounds of this invention may be in crystalline or non-crystalline form, and, if crystalline, may optionally be hydrated or solvated. This invention includes within its scope stoichiometric hydrates as well as compounds containing variable amounts of water.


The invention extends to all isomeric forms including stereoisomers and
20 geometric isomers of the compounds of formula (I) including enantiomers and mixtures thereof e.g. racemates. The different isomeric forms may be separated or resolved one from the other by conventional methods, or any given isomer may be obtained by conventional synthetic methods or by stereospecific or asymmetric syntheses.

25 Since the compounds of formula (I) are intended for use in pharmaceutical compositions it will readily be understood that they are each preferably provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure and preferably at least 85%, especially at least 98% pure (% are on a weight for weight basis). Impure preparations of the compounds may be used for preparing the
30 more pure forms used in the pharmaceutical compositions.

Compounds of formula (I) are imidazole derivatives which may be readily prepared using procedures well-known to those skilled in the art, and described in, for instance, *Comprehensive Heterocyclic Chemistry*, Editors Katritzky and Rees, Pergamon Press, 1984, **5**, 457-497, from starting materials which are either
35 commercially available or can be prepared from such by analogy with well-known processes. A key step in many such syntheses is the formation of the central

5

10



15



wherein Y₁ is a group convertible to Y, and R² and R³ is as hereinbefore defined, or an equivalent thereof, and, if necessary, with ammonia or a source thereof, under imidazole-ring forming conditions.

20

30

Ammonia, or a source thereof, is preferably used in excess, with at least a dimolar amount being used in the case of the alpha-diketone and at least an equimolar amount in the case of the alpha-keto-oxime.

Suitable sources of ammonia include ammonium salts of organic carboxylic acids, such as ammonium trifluoroacetate or an ammonium C₁₋₆ alkanoate, for instance ammonium acetate and ammonium formate, preferably ammonium acetate, and carboxylic amides, in particular of formic acid, such as formamide. An ammonium salt is generally used in large excess and in the presence of an acid, such as a C₁₋₆ carboxylic acid which acid may also be used as a solvent for the reaction. If formamide is used, this may be used in excess, as the reaction solvent. An alternative solvent such as ethanol or dimethyl sulphoxide (Lantos *et al*, J Het Chem, 19, 1375, 1982) may be used. An additional solvent may also be employed, for instance, dimethyl formamide may be used with formamide. The reaction is generally carried out at elevated temperatures, for instance under reflux conditions, and if desired, in a sealed vessel optionally under pressure and/or an inert gas atmosphere, for instance nitrogen. It is also possible to run the reaction at elevated temperature in a molten salt, which contains a source of ammonia, for example in ammonium trifluoroacetate.

A further suitable source of ammonia is hydroxylamine, in which case the initially formed imidazole is an N-hydroxy-N-oxide imidazole. This may then be reduced to the corresponding N-hydroxy imidazole by treating with a suitable reducing agent such as sodium borohydride, in an appropriate solvent such as methanol, following the method of Akange and Allan, Chem and Ind, 5 Jan 1975, 38. The N-hydroxy imidazole may in turn be converted to an imidazole of formula (I) by treatment with a conventional deoxygenating agent such as titanium trichloride, phosphorus trichloride or a trialkylphosphite such as trimethyl- or triethyl-phosphite. N-hydroxy-N-oxide imidazoles may be readily obtained by treating an alpha-diketone of formula (II) with an aldehyde of formula (III) with about two equivalents of hydroxylamine or the corresponding aldoxime and about one equivalent of hydroxylamine, under proton catalysis. Alternatively, the N-oxide may be obtained by the acid catalyzed condensation of the corresponding alpha-dioxime or alpha-keto-oxime with an aldoxime of the aldehyde of formula (III).


When the compound of formula (II) above is an alpha-keto-oxime derivative, it will be appreciated that the product initially obtained will be a compound of formula (I) in which the imidazole is N-hydroxylated and which may be converted into a compound of formula (I) as described above.

It will be appreciated by those skilled in the art that in some instances, it will not be necessary to provide a separate source of ammonia as the alpha-diketone or aldehyde equivalent may already contain such a source. Examples of this include alpha-dioxime or alpha-keto-oxime and aldoxime.

5


Preferred methods for preparing compounds of this invention are as outlined in the Schemes I-III.

In Scheme I, the anion prepared from **1** (a specific example being $V = CH$, $X = S$, $R_1 = Me$), by treatment with a strong base such as lithium di-*iso*-propylamide, is condensed with an aryl aldehyde, to give, after removal of the protecting group, the diol **2**. This may then be converted to the alpha-diketone **3** by a Swern oxidation of which any number of potentially useful variations are known and may be used. The alpha-diketone **3** is then cyclised to an imidazole **4** by heating **3** with a substituted aldehyde of formula (III) in a mixture of ammonium acetate, as the source of ammonia, and an appropriate solvent, for example acetic acid or DMSO. The imidazole **4**, with the group Y_1 may be converted into a group Y using conventional functional group interconversion procedures to afford imidazole **5**, a compound of formula I. Functional group transformations are well known in the art and are described in, for instance, *Comprehensive Organic Functional Group Transformations*, eds. A.R. Katritzky, O. Meth-Cohn, and C.W. Rees (Elsevier Science Ltd., Oxford, 1995), *Comprehensive Organic Chemistry*, eds. D. Barton and W.D. Ollis (Pergamon Press, Oxford, 1979), and *Comprehensive Organic Transformations*, R.C. Larock (VCH Publishers Inc., New York, 1989). An example of a preferred Y_1 group is CH_2NH_2 or a protected form thereof e.g. CH_2NHBoc . Scheme I also illustrates the preparation of a protected alpha-hydroxyketone **6**, by condensing the anion of **1** with an appropriately activated carbonyl derivative of a substituted benzamide, such as the N-methoxy-N-methylamide, to yield a protected alpha-hydroxyketone. This adduct **6** may then be directly converted to the imidazole **4**, using a combination of a copper (II) salt, such as copper (II) acetate, as an oxidizing agent and ammonium acetate as a source of ammonia. The alpha-hydroxyketone **6** may also be deprotected and then oxidized to give an alpha-diketone **3**, for instance using Swern oxidation.



Scheme I


- 5 Scheme II illustrates the use of an alpha-keto-oxime for preparing a compound of formula (I). A heterocyclic ketone **7** (for example, V = N, X = S, R₁ = Me) is prepared by adding the anion of 2-methylthio-6-methylpyrimidine (prepared by treatment thereof with an alkyl lithium, such as *n*-butyl lithium) to an N-alkyl-O-alkoxybenzamide. Alternatively, the anion may be condensed with a
- 10 benzaldehyde, to give an alcohol that is then oxidized to the ketone **7**. The alpha-keto-oxime **8** is then prepared from **7** using standard conditions, such as reaction with sodium nitrite, and this may then be reacted with an aldehyde of formula (III) to afford an N-hydroxyimidazole **9**. This may be converted to **10**, by treating it with a
- 15 deoxygenating agent such as titanium trichloride, phosphorus trichloride or a trialkyl phosphite, such as trimethyl or triethylphosphite. Functional group interconversion then may be employed to convert Y₁ of **10** to afford **11**, a compound of formula (I) with Y as hereinbefore defined. Furthermore, oxidation of the sulfur (X = S) of **5** or **11** to the sulfoxide or sulfone followed by nucleophilic displacement with oxygen, nitrogen or sulfur nucleophiles affords compounds of
- 20 Formula I (X = O, N, or S; compounds **5** and **11** in Schemes I and II).



Scheme II

- 5 Compounds of the general formula ($\text{V} = \text{CH}$, $\text{X} = \text{O}, \text{N}, \text{S}$) can be prepared as in Schemes I or II except substituting 4-methyl-2-chloropyridine or 4-methyl-2-fluoropyridine for the starting 2-methylthio-6-methylpyrimidine or pyridine (1) (Gallagher *et al Bioorg. Med. Chem.* 5, 49, 1997). Nucleophilic substitution of the resulting 2-halopyridinylimidazole can be effected by the procedure described in
- 10 United States Patent 5,670,527. Alternatively, oxidation of the sulfur ($\text{X} = \text{S}$) to the sulfoxide or sulfone followed by nucleophilic displacement with oxygen, nitrogen or sulfur nucleophiles affords compounds of Formula I (compounds 5 and 11 in Schemes I and II).

- 15 Alternatively compounds may be prepared as in Scheme III wherein the Ar group is added last. (X , R^2 , R^3 , and Y are as defined for formula (I), and Y_1 is a group convertible to Y).



Scheme III

Oxidation of a 4-acetyl substituted pyridine derivative ($V = CH$, $X = S$, $R_1 = Me$) with sodium nitrite affords the ketooxime. Heating this product with an alkyl aldehyde and ammonium acetate in acetic acid allows access to the imidazole nucleus. Reduction of the hydroxyimidazole may be accomplished with heating with a trialkyl phosphite or stirring at ambient temperature with titanium trichloride. Treatment of the imidazole with N-iodosuccinimide gives the iodoimidazole which then may be reacted with various boronic acids under palladium catalysis to give the aryl or heteroaryl imidazoles. Alternative biaryl coupling reactions may also be used.

During the synthesis of the compounds of formula (I) labile functional groups in the intermediate compounds, e.g. hydroxy, carboxy and amino groups, may be protected. A comprehensive discussion of the ways in which various labile functional groups may be protected and methods for cleaving the resulting protected derivatives is given in for example *Protective Groups in Organic Chemistry*, T.W. Greene and P.G.M. Wuts, (Wiley-Interscience, New York, 2nd edition, 1991).

The compounds of formula (I) may be prepared singly or as compound libraries comprising at least 2, for example 5 to 1,000 compounds, and more preferably 10 to 100 compounds of formula (I). Libraries of compounds of formula (I) may be prepared by a combinatorial 'split and mix' approach or by multiple parallel synthesis using either solution phase or solid phase chemistry, by procedures known to those skilled in the art.

Thus according to a further aspect of the invention there is provided a compound library comprising at least 2 compounds of formula (I), or pharmaceutically acceptable salts thereof.

Pharmaceutically acceptable salts may be prepared conventionally by reaction with the appropriate acid or acid derivative.

METHODS OF TREATMENT

The Tie receptors are proteins of approximately 125 kDa, with a single putative transmembrane region. The extracellular domain of these receptors is divided into several regions: there are 3 regions that have a pattern of cysteine expression found in EGF-like domains; there are 2 regions that have some weak homology to and structural characteristics of immunoglobulin-like domains; and there are 3 regions with homology to the fibronectin III repeat structure. This particular combination of extracellular domains is unique to the Tie receptors. The

intracellular portion of Tie2 is most closely related (~40 % identity) to the kinase domains of FGF-R1, PDGF-R and c-kit. The intracellular portions of Tie2 contain all of the features of tyrosine kinases, including a GXGXXG ATP binding site consensus sequence and typical tyrosine kinase motifs (i.e., HRDLAARN and DFGL).

These receptors have sparked interest because they are the only receptor tyrosine kinases, other than those receptors for vascular endothelial cell growth factor (VEGF), that are largely restricted to endothelial cells in their expression. There are several lines of evidence showing that Tie2 is important in angiogenesis, detailed in the following paragraphs.

a. Tie1 and Tie2 receptor location

i. Embryological vascular development

The location of the Tie receptors in the embryo has been studied by a number of investigators using *in situ* hybridization. Korhonen et al. (*Blood* 80:2548-2555, 1992) showed that the mRNA for Tie receptors is located in endothelial cells of all forming blood vessels and in the endocardium of mouse embryos. During embryonic development, expression of the Tie receptors is seen in angioblasts and all developing vasculature. Expression of the Tie receptors follows expression of the major VEGF receptor, Flk-1, by 12-24 hours during mouse embryogenesis, perhaps suggesting sequential and different actions of these receptor systems (Schnurch and Risau, *Development* 119: 957-968, 1993). Cloning of a 1.2 Kb genomic 5' flanking region of Tie2, coupled to a lacZ gene and expressed in transgenic mice, demonstrated a selective pattern of expression in endothelial cells during embryonic development (Schlaeger et al., *Development* 121:1089-1098, 1995). Thus, the Tie2 promoter acts to assure endothelial cell-specific expression of Tie2.

ii. In adult tissues

The similarities between embryonic angiogenesis and pathologic angiogenesis yields the hypothesis that blocking Tie2 function, in tumors or chronic inflammatory settings, for examples, may block angiogenesis, thus blocking further cell proliferation and provide therapeutic benefit. Tie mRNA cannot be observed in adult skin, except at sites of active wound healing, where the proliferating capillaries in the granulation tissue contain abundant Tie mRNA (Korhonen et al., *Blood* 80:2548-2555, 1992). PCR amplification of cDNA from normal skin fails to show a signal for Tie receptor (Kaipainen et al., *Cancer Res.* 54:6571-6577, 1994). In contrast, a strong signal is seen with cDNA from metastasizing melanomas, where

in situ studies localize this signal to the vascular endothelium. While Tie receptor expression is down-regulated in the established vasculature, it is upregulated in the angiogenesis that occurs in the ovary during ovulation, in wounds and in tumor (breast, melanoma and renal cell carcinoma) vasculature, consistent with prevailing views that angiogenesis in the adult borrows from embryonic angiogenic mechanisms.

b. Tie knockout animals

Homozygous mice with a Tie2 knockout, or carrying a transgene encoding a "dominant-negative" Tie2 receptor, confirmed that the Tie2 receptor is critical for embryonic development (Dumont et al., *Genes Dev.* 8:1897-1909, 1994; Sato et al., *Nature* 376:70-74, 1995). Embryonic death in these mice occurred due to vascular insufficiency and there were dramatically reduced numbers of endothelial cells. Vasculogenesis - that is the differentiation of endothelial cells and the *in situ* formation of vessels - appeared relatively normal in mice lacking Tie2. The subsequent sprouting and remodelling resulting in formation of vessel branches (angiogenesis) was drastically reduced in the Tie2 mutant mice embryos. This lack of sprouting and angiogenesis resulted in substantial growth retardation, particularly of the brain, neural tube and heart, resulting in lack of viability. This exemplifies the critical importance of Tie2 in angiogenesis. This is significant, as angiogenesis is regulated by a number of growth factors. Interestingly, Flk1 (VEGF receptor) knockout mice exhibit embryo lethal defects in vasculogenesis that occur earlier than those of Tie2 disruption. Disruption of the Tie1 receptor yields a much different, and later, defective phenotype; the mouse embryo dies late in development due to haemorrhage resulting from defective integrity of an otherwise well formed vasculature. Taken together, these studies suggest that the VEGF/Flk1 and Tie systems operate in sequential fashion, with Tie2 having a critical role in angiogenesis.

c. Tie2 ligands

Recently, two ligands for the Tie2 receptor have been reported. Angiopoietin-1 binds and induces the tyrosine phosphorylation of Tie2 and its expression *in vivo* is in close proximity with developing blood vessels (Davis et al., *Cell* 87:1161-1169, 1996). Mice engineered to lack Angiopoietin-1 display angiogenic deficits reminiscent of those previously seen in mice lacking Tie2 receptors, demonstrating that Angiopoietin-1 is a primary physiologic ligand for Tie2 and that Tie2 has critical *in vivo* angiogenic actions (Suri et al., *Cell* 87:1171-1180, 1996). Angiopoietin-2 was identified by homology screening and shown to be

a naturally occurring antagonist for Tie2 receptors. Transgenic overexpression of Angiopoietin-2 disrupts blood vessel formation in the mouse embryo (Maisonpierre et al., *Science* 277:55-60, 1997). Together, these results support a role for Tie2 receptors in angiogenesis.

5

In order to use the compounds of formula (I) in therapy, they will normally be formulated into a pharmaceutical composition in accordance with standard pharmaceutical practice.

According to a further aspect of the invention there is provided a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

No toxicological effects are indicated/expected when a compound of formula (I) is administered in the above mentioned dosage range.

Compounds of Formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions incorporating such may conveniently be administered by any of the routes conventionally used for drug administration, for instance, orally, topically, parenterally or by inhalation. The compounds of Formula (I) may be administered in conventional dosage forms prepared by combining a compound of Formula (I) with standard pharmaceutical carriers according to conventional procedures. The compounds of Formula (I) may also be administered in conventional dosages in combination with a known, second therapeutically active compound. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation. It will be appreciated that the form and character of the pharmaceutically acceptable character or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

The pharmaceutical carrier employed may be, for example, either a solid or liquid. Exemplary of solid carriers is lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary of liquid carriers is syrup, peanut oil, olive oil, water and the like. Similarly, the carrier or diluent may include time delay material well known to the art, such as glyceryl mono-stearate or glyceryl distearate alone or with a wax.

A wide variety of pharmaceutical forms can be employed. Thus, if a solid carrier is used, the preparation can be tableted, placed in a hard gelatin capsule in

powder or pellet form or in the form of a troche or lozenge. The amount of solid carrier will vary widely but preferably will be from about 25mg. to about 1g. When a liquid carrier is used, the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampule or nonaqueous liquid suspension.

Compounds of Formula (I) may be administered topically, that is by non-systemic administration. This includes the application of a compound of Formula (I) externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the blood stream. In contrast, systemic administration refers to oral, intravenous, intraperitoneal and intramuscular administration.

Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose. The active ingredient may comprise, for topical administration, from 0.001% to 10% w/w, for instance from 1% to 2% by weight of the formulation. It may however comprise as much as 10% w/w but preferably will comprise less than 5% w/w, more preferably from 0.1% to 1% w/w of the formulation.

Lotions according to the present invention include those suitable for application to the skin or eye. An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops. Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil.

Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy base. The base may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as almond, corn, arachis, castor or olive oil; wool fat or its derivatives or a fatty acid such as steric or oleic acid together with an alcohol such as propylene glycol or a macrogel. The formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as a sorbitan ester or a polyoxyethylene derivative thereof.

Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as siliceous silicas, and other ingredients such as lanolin, may also be included.

5 Drops according to the present invention may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and preferably include a surface active agent. The resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98-
10 100°C for half an hour. Alternatively, the solution may be sterilized by filtration and transferred to the container by an aseptic technique. Examples of bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01%). Suitable solvents for the preparation of an oily solution, include glycerol,
15 diluted alcohol and propylene glycol.

Compounds of formula (I) may be administered parenterally, that is by intravenous, intramuscular, subcutaneous intranasal, intrarectal, intravaginal or intraperitoneal administration. The subcutaneous and intramuscular forms of parenteral administration are generally preferred. Appropriate dosage forms for
20 such administration may be prepared by conventional techniques. Compounds of Formula (I) may also be administered by inhalation, that is by intranasal and oral inhalation administration. Appropriate dosage forms for such administration, such as an aerosol formulation or a metered dose inhaler, may be prepared by conventional techniques.

25 The compounds of Formula (I) may also be used topically in the treatment or prophylaxis of disease states exacerbated by excessive or inappropriate angiogenesis.

The compounds of Formula (I) are administered in an amount sufficient to inhibit Tie2 receptor activity such that it is regulated down to normal levels, or in
30 some case to subnormal levels, so as to ameliorate or prevent the disease state.

Chronic diseases which have an inappropriate angiogenic component are various ocular neovascularizations, such as diabetic retinopathy and macular degeneration.

35 Other chronic diseases which have an excessive or increased proliferation of vasculature are tumor growth and metastasis, atherosclerosis, and certain arthritic

conditions. Therefore Tie2 tyrosine kinase receptor inhibitors will be of utility in the blocking of the angiogenic component of these disease states.

The term "excessive or increased proliferation of vasculature inappropriate angiogenesis" as used herein includes, but not limited to, diseases which are characterized by hemangiomas and ocular diseases. The term "inappropriate angiogenesis" as used herein includes, but not limited to, diseases which are characterized by vessel proliferation with accompanying tissue proliferation, such as occurs in cancer, metastasis, arthritis, psoriasis and atherosclerosis.

For all methods of use disclosed herein for the compounds of Formula (I), the daily oral dosage regimen will preferably be from about 0.1 to about 80 mg/kg of total body weight, preferably from about 0.2 to 30 mg/kg, more preferably from about 0.5 mg to 15mg. The daily parenteral dosage regimen will be from about 0.1 to about 80 mg/kg of total body weight, preferably from about 0.2 to about 30 mg/kg, and more preferably from about 0.5 mg to 15mg/kg. The daily topical dosage regimen will preferably be from 0.1 mg to 150 mg, administered one to four, preferably two or three times daily. The daily inhalation dosage regimen will preferably be from about 0.01 mg/kg to about 1 mg/kg per day. It will also be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of a compound of Formula (I) or a pharmaceutically acceptable salt thereof will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of a compound of Formula (I) or a pharmaceutically acceptable salt thereof given per day for a as defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.

PHARMACOLOGICAL TEST METHODS

A. Measurement of Tie2 kinase activity

A partial cDNA clone for the Tie2 receptor was used to make protein for Tie kinase studies. In order to generate the primary screening assay, a baculovirus expressed GST fusion for Tie2 kinase domain was constructed and expressed using the commercial vector pAcG1 (Pharminogen).

This final construct was transfected into Baculovirus and soluble GST fusion products used in the screening assay. Prior work had demonstrated the use of a

baculovirus expressed GST fusion for the murine Tie2 kinase domain to screen for candidate target/signaling molecules (Huang *et al.*, Oncogene 11:2097-2103, 1995).

5 **Tie2 kinase activity assay:** The Tie2 kinase activity assay was typically run in one of 2 ways described as follows. Minor variations in the assay give similar results.

1. Autophosphorylation flashplate assay

Materials:

Kinase buffer (final 20 mM Tris-HCl, pH7.0, 100 mM NaCl, 12 mM MgCl₂, 1 mM DTT).

10 Gamma ³³P-ATP (usually final amount of 0.5-1 uCi/well)

ATP (final 30 uM, or other desired concentration)

Flashplate (96-well, polystyrene microplate with plastic scintillator coated wells)

TopCount (microplate scintillation counter)

Procedures:

15 Turn on incubator shaker and adjust temperature to 30° C.

Add 20 ul of 3X kinase buffer per well to the Flashplate

Add 20 ul of protein per well except for background. Compounds added, typically in DMSO stocks, at 1-2 ul.

Add 20 ul mixture of gamma ³³P-ATP and cold ATP per well.

20 Total volume is 60 ul.

Cover with transparent polyester film.

Incubate at 30°C for two hours in shaker, or desired time.

Take Flashplate out of the shaker, wash five times (for example, with 300 ul of 10 uM ATP in 1X PBS per well).

25 Read plate on TopCount or other counting instrument. Results are calculated as % inhibition

and IC₅₀, using normal calculation methods.

Representative compounds of Formula (I), Example 1 was found to be active in the assay, having an IC₅₀ of < 1 uM.

30

2. Fluorescence Polarization for Tie 2 Kinase

Final Assay conditions:

50 mM HEPES pH 7.5

2% DMSO (when screening compounds)

35 250 uM ATP

2 mM MgCl₂

1 mM DTT

50 uM NaVanidate

10 uM peptide substrate

activated tie 2 kinase * see activation protocol below

5 Peptide Substrate:

RFWKYEFWR-OH

MW (TFA salt) = 1873 Da

Make a 1 mM peptide stock and store at -20°C.

Dilute to 100 uM just prior to use.

10 9X Kinase buffer:

450 mM HEPES pH 7.5

900 mM NaCl

450 uM NaVanidate

18 mM MgCl₂

15 100 mM DTT

Can be made up ahead of time and stored in aliquots at -20°C.

ATP stock:

Make a 25 mM ATP stock and store in aliquots at -20°C until needed.

Dilute to 2.5 mM prior to use.

20 Procedure:

For a 50 ul reaction add the following to each well of a 96-well black half-area plate (Costar, cat# 3694)

1. 5 ul of compound in 20% DMSO

2. 5 ul 9X kinase buffer.

25 3. 5 ul 2.5 mM ATP.

4. 5 ul 100 uM peptide substrate.

5. 25 ul PTK detection mix (Panvera, P-2652, 50ml - UK distributor is Cambridge Bioscience)

30 6. 5 ul activated tie 2 kinase (protocol below) diluted in 1X buffer to initiate the reaction.

7. Read polarization on an FP instrument cycling for 30-50 minutes in accordance with enzyme activity.

Representative compounds of Formula (I), Example 1 was found to be active in this fluorescence assay, having an IC₅₀ of < 1 uM.

35

Activation of Tie 2 Kinase Protocol:

Final Buffer Conditions:

- 20 mM Tris-HCl pH 7.5
- 12 mM MgCl₂
- 100 mM NaCl
- 5 20 uM NaVanadate
- 1 mM DTT
- 300 uM ATP

Procedure

1. Incubate 5 uM Tie 2 kinase in the 300 uM ATP and the buffering conditions
- 10 described above.
2. Allow to incubate at 27°C for 2 hours.
3. Add 2.5 ml reaction to a NAP-25 desalting column (Pharmacia Biotech cat. no. 17-0852-02) pre-equilibrated in 20 mM Tris-HCl pH 7.5, 100 mM NaCl₂ to separate the ATP from the enzyme.
- 15 4. Elute the enzyme with 5.0 ml 20 mM Tris-HCl pH 7.5, 100 mM NaCl₂; the protein concentration should be 2.5 uM at this point.
5. Aliquot out the enzyme and store at -80°C as soon as possible.

B. Measurement of Tie2 receptor signal transduction - a cellular assay

- 20 HEL cells (ATCC # TIB180) are cultured at between 1 and 5x10⁵ ml in RPMI-1640 medium supplemented with 2 mM glutamine and 10% FBS as a suspension culture. Sixteen to thirty-six hours prior to an experiment, the necessary number of cells are passaged into 0.5% FBS/RPMI medium. On the day of an experiment, cells are harvested and resuspended at a density of 0.5 - 1.0 x10⁷ cells
- 25 ml in 0.5% FBS RPMI and seeded at 2-3 ml/well in six well plates.

- Alternatively, Human Umbilical Vein Endothelial Cells (HUVECs) (Clonetics – Walkersville, MD) may be used for the assay. HUVECs between passages 2 and 12, are plated at 2 x10⁵ and 1 x 10⁶ cells per well in a six well plate in supplemented EGM (Clonetics). After 24 hours the media is changed to EBM
- 30 containing 3% BSA (Clonetics), and the cells are cultured overnight and used for assay the following day.

- Cells are treated with inhibitory compounds at appropriate concentrations for 30-45 minutes. The contents of the wells are mixed briefly on a rocker (approx. 30 seconds) and then incubated at 37°C. The cells are then treated with a source of
- 35 native ligand, such as serum or fibroblast conditioned medium for 10 minutes

At the end of 10 minute incubation period the plate is placed on ice. The cells are harvested and the media is removed. The cells are lysed in denaturing sample buffer (Invitrogen – Carlsbad, CA). The suspension is sonicated for 5 pulses at a medium setting and returned to ice. The phosphorylation state of the Tie2 receptor is determined Western blotting and detection by an anti-phospho-Tie2 antibody, as detailed below (Harlow, E., and Lane, D.P., Antibodies - A Laboratory Manual, Cold Spring Harbor Laboratory Press: New York, 1988.). Thirty ul of the lysate are run on a 7.5% SDS/polyacrylamide gel. The gel is then transferred to a nitrocellulose or PVDF membrane as per the manufacturer's instructions for Western blotting.

The blots are washed with PBS 0.05% between-20 and then blocked with 3% BSA/ PBS/Tween for 1 hour at room temperature. The blots are then incubated with 1 ug/ml anti-phospho-Tie2 antibody (SmithKline Beecham) in PBS/0.05% Tween for 1 hour. The blot is then washed 4 times with PBS/Tween for 5 minutes each. The blot is incubated with an anti-mouse-HRP conjugate secondary antibody at the dilution recommended by the manufacturer, in PBS/Tween for 1 hour. The blot is washed in PBS/Tween, 4 times for 5 minutes each. After the last wash, the blot is developed by the ECL method (Amersham) or some equivalent.

Using a densitometer or graphics program (e.g. ImageQuant – Molecular Dynamics), each blot is scanned. The Tie-2 band is isolated and "boxed out" for each lane. The pixel volume or comparable measure for each sample is analyzed. Also, an appropriate background region of the same dimensions is determined for each sample. After adjusting for background, phbsphorylation is expressed as the ratio of phosphotyrosine staining, relative to the untreated control.

25

Angiogenesis in vivo Model

Measurement of angiogenesis *in vivo* - Murine air pouch granuloma model:

Described below a model of inflammatory angiogenesis used to show that inhibition of Tie2 will stop the tissue destruction of excessive or inappropriate proliferation of blood vessels. The murine airpouch granuloma model of chronic inflammation (Kimura *et al.*, 1985, *J. Pharmacobio-Dyn.*, 8:393-400; Colville-Nash *et al.*, 1995, *J. Pharm. and Exp. Ther.*, 274:1463-1472) whose disclosure is incorporated herein by reference in its entirety, is characterized by inflammatory cell influx, fibrous tissue proliferation and intense angiogenesis. It is representative of inflammatory angiogenesis and demonstrates that the angiogenic component can be

35

pharmacologically modulated independently of granuloma growth and size. In addition, angiogenesis can be accurately quantitated by a vascular casting method.

Day 1, mice are anesthetized using Aerrane (isoflurane) gas (5%) or other approved methods, after which 3mls of air is injected into the dorsal subcutaneous tissue using a 27g needle. Mice are allowed to recover.

Day 0, mice are again anesthetized using Aerrane or other approved methods, once anesthetized 0.5ml of Freunds complete adjuvant with 0.1% v/v croton oil is injected into the air pouch formed on Day -1. The animals also begin their dosing regime (number of day's dependent upon study) with the animals typically receiving compound in 0.2ml N,N, Dimethyl Acetoacetamide(DMA) (Sigma, St. Louis, Mo.)/Cremephor El (Sigma, St. Louis, Mo.), saline (10/10/80) or other appropriate vehicle. The animals are allowed to recover and all subsequent dosing is performed on the animals in the absence of anesthetics.

Days 1-5, animals are dosed according to schedule.

On Day 6 the animals are again anesthetized after which a vascular cast is made (Kimura et al., 1986, *J.Pharmacobio-Dyn.*, 9:442-446); this involves a 1ml tail vein i.v. injection of a Carmine Red (10%) (Sigma, St. Louis, Mo.) / gelatin (5%) (Sigma, St. Louis, Mo.) solution. The animals are then sacrificed by lethal dose of anesthesia and chilled at 4°C for 2 hours prior to the removal of the granuloma tissue.

When the granuloma is removed it is weighed and then dried for 3 days at 45°C and reweighed. The dried tissue is then digested in 0.9ml of a 0.05M phosphate buffer pH 7.0 containing 12 U /ml⁻¹ papain (Sigma, St. Louis, Mo.) and 0.33g / L⁻¹ N-acetyl-L-Cysteine (Sigma, St. Louis, Mo.) at 57°C for 3 days. After 3 days digestion the carmine red is solublized by the addition of 0.1ml 5mM NaOH. Samples are centrifuged and then filtered using 0.2 um acrodiscs. The carmine content is then determined against a carmine red standard curve (0.5 to 2 mg/ml) generated in extracted tissue from non carmine treated animals and read at 490nm. Sample and standard values are determined typically using DeltaSoft Elisa analysis software (Biometallics Inc., Princeton, NJ). The carmine content is then used to determine the vascular indexes for the various treatments, vascular index being the mg carmine dye/ gm dry tissue.

The effect of compounds on vascular density was typically measured for 6 days after induction of the granuloma. This time point has been determined to be at or near the peak of angiogenesis. As a positive control medroxyprogesterone, an angiostatic steroid (Gross *et al.*, 1981, *Proc. Natl. Acad. Sci. USA*, 78:1176-1180),

whose disclosure is hereby incorporated by reference in its entirety, was utilized. This control demonstrated a maximum reduction of 50% in this model. Medroxyprogesterone had no effect on granuloma size as measured by dry weight.

5 **Angiogenesis Model – in vivo**

Measurement of angiogenesis *in vivo* - Matrigel model:

Angiogenesis is modeled in-vivo by placing an extra-cellular matrix gel, beneath the skin of a mouse for approximately one week, and then employing several measures to quantitate angiogenic invasion of the gel (Biancone,L, et. al. Development of
10 Inflammatory Angiogenesis by Local Stimulation of Fas In Vivo. J. Exp. Med. 186:147, 1997.) . Briefly, reduced growth factor, endotoxin free Matrigel® (Becton-Dickinson, Bedford, MA) is a gel at low temperatures. Antibodies or known angiogenic agents are mixed with the gel, such that they do not constitute more than 2% of the total volume. Eight week old or older, C57 female mice are
15 administered 0.5ml of the Matrigel® by dorsal subcutaneous injection through chilled syringes. At physiological temperature, the liquid Matrigel® rapidly forms a solid and cohesive gel. During the course of the experiment, mice receive test compounds or controls administered as described above. After six days, the mice are sacrificed and the Matrigel® plugs recovered. Angiogenesis is quantitated by
20 analyzing the hemoglobin content of the gel by the method of Drabkin (Drabkin,DL and Austin,JH: Spectrophotometric Studies II. Preparations from washed blood cells; nitric oxide hemoglobin and sulfhemoglobin. J Biol Chem 112:51, 1935.)(Sigma, St. Louis, MO), or by staining and quantitating blood vessel with CD31 staining as described above.

25

SYNTHETIC CHEMISTRY

The invention will now be described by reference to the following examples which are merely illustrative and are not to be construed as a limitation of the scope of the present invention. All temperatures are given in degrees centigrade, all
30 solvents are highest available purity and all reactions run under anhydrous conditions in an argon atmosphere unless otherwise indicated.

In the Examples, all temperatures are in degrees Centigrade (°C). Mass spectra were performed upon a VG Zab mass spectrometer using fast atom bombardment, unless otherwise indicated. ¹H-NMR (hereinafter "NMR") spectra
35 were recorded at 250 MHz using a Bruker AM 250 or Am 400 spectrometer. Multiplicities indicated are: s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet


and br indicates a broad signal. Sat. indicates a saturated solution, eq indicates the proportion of a molar equivalent of reagent relative to the principal reactant.

Flash chromatography is run over Merck Silica gel 60 (230 - 400 mesh).

5

Example 1

(2-(4-(6-methoxynaphthalen-2-yl)-5-pyridin-4-yl-1*H*-imidazol-2-yl)-2-methyl-propyl)-carbamic acid *tert*-butyl ester



a) 6-Methoxy-naphthylene-2-carboxylic acid-*N*-methoxy-*N*-methyl-amide

10 A suspension of 6-methoxynaphthoic acid (10.95grams (hereinafter "g"), 0.05 moles (herein after "mol"), triethylamine (29.8 milliliters (hereinafter "mL" or "ml")), 0.2mol) in dichloromethane (150ml) was cooled to 0°C and slowly thionyl chloride (4.35ml) was added, upon which the solution became brown and homogenous. The ice bath was removed and continued stirring at room temperature
15 for about 1 hour (hereinafter "h") at which point *N*-methoxymethylamine hydrochloride (7.02g, 0.06mol) was added. The mixture was stirred at room temperature for 3 hours. The solution was concentrated and the residue was partitioned between dichloromethane and saturated potassium carbonate solution. The organic layer was separated, washed with brine dried over anhydrous
20 magnesium sulphate, filtered and concentrated at reduced pressure to give the title compound (9.65g, 73%) as a brown solid; MS(ES) *m/e* 246 [M+H]⁺.

b) 4-*t*-Butyldimethylsiloxyethylpyridine

4-Pyridylcarbinol (8.5g, 0.08mol) was dissolved in a 9:1 mixture of *N,N*-dimethylformamide and dichloromethane (150mL). *t*-Butyldimethylsilylchloride
25 (13g, 0.09mol) and imidazole (6.4g, 0.09mol) were added and the solution was stirred for 12 hours at room temperature. The reaction mixture was concentrated at reduced pressure and the residue was partitioned between ethyl acetate and water. The organic layer was separated, dried over anhydrous magnesium sulphate, filtered and concentrated at reduced pressure to give the title compound (17.4g, 92%) as a
30 colorless oil; MS(ES) *m/e* 244 [M+H]⁺.


c) 1-(*t*-Butyl-dimethylsiloxy)-2-(6-methoxy-naphthalen-2-yl)-1-pyridin-4-yl-ethan-2-one

To a stirring solution of diisopropylamine (5.01 mL, 0.035 mol) in tetrahydrofuran (50 mL) at 0°C was added n-butyl lithium 15.5 mL, 0.039 mol) to generate lithium diisopropylamide in situ. To the cooled -78°C LDA solution was added 4-t-butyl dimethylsiloxy pyridine (7.84 g, 0.035 mol) and stirring was continued for 30 minutes at which time 6-methoxynaphthalene-2-carboxylic acid-N-methoxy-N-methyl-amide (5.51 g, 0.023 mol) was added. The reaction was gradually allowed to warm to room temperature. The reaction mixture was extracted with ethyl acetate and the organic layers were combined, dried over anhydrous magnesium sulphate, filtered and concentrated at reduced pressure. The title compound was purified by flash chromatography and isolated as a yellow solid; MS(ES) m/e 377 [M+H]⁺.
 d) (2-(4-(6-methoxy-naphthalen-2-yl)-5-pyridin-4-yl-1-imidazol-2-yl)-2-methyl-propyl)-carbamic acid tert-butyl ester

Acetic acid (15 ml) was added into a mixture of (2,2-dimethyl-3-oxo-propyl)-carbamic acid *tert*-butyl ester (Y. Guindon *et al.*, *J. Am. Chem. Soc.*, **1997**, *119*, 9289) (0.26 g, 1.2 mmol), ammonium acetate (0.98 g, 12.0 mmol), and 2-(t-butyl-dimethylsilyloxy)-2-(6-methoxy-naphthalen-2-yl)-1-pyridin-4-yl-ethanone (0.26 g, 0.6 mmol). The resulting solution was heated at 90 °C overnight, then cooled to 0 °C, and NH₄OH was added to the solution slowly with stirring. The resulting precipitate was filtered, and dried to yield the title compound; MS(ES) m/e 472 [M+H]⁺.

Example 2


2-(4-(6-methoxy-naphthalen-2-yl)-5-pyridin-4-yl-1-imidazol-2-yl)-2-methyl-propylamine



The product of Example 1 (200 milligrams (hereinafter "mg"), 0.4 millimoles (hereinafter "mmol")) was dissolved in a 1:1 mixture of trifluoroacetic acid and dichloromethane (5 mL) and stirred at room temperature for 4 hours. The solvents were concentrated at reduced pressure. The crude product was purified by column chromatography to afford the title compound (50 mg, 32%). MS(ES) m/e 373 [M+H]⁺.

Example 3

n-Propyl-(2-(4-(6-methoxy-naphthalen-2-yl)-5-pyridin-4-yl-1*H*-imidazol-2-yl)-2-methyl-propyl)-(3-methylsulfanyl-propyl)-amine




- 5 A solution of Example 2 (20mg, 0.05mmol) in *N,N*-dimethylformamide (2ml) was treated with potassium carbonate (10mg, 0.07mmol) and 1-bromopropane (9mg, 0.07mmol). The solution was stirred at room temperature for 4 hours. The mixture was diluted with water and extracted with ethyl acetate. The aqueous layer was separated and extracted with additional ethyl acetate, the organic layers were
- 10 combined, dried over anhydrous magnesium sulphate, filtered and concentrated at reduced pressure. The residue was chromatographed on a Gilson HPLC to give the title compound (3mg, 13%) as a yellow solid; MS(ES+) *m/e*. 415 [M+H]⁺.

15

Example 4


(2-(4-(6-methoxy-naphthalen-2-yl)-5-pyridin-4-yl-1*H*-imidazol-2-yl)-2-methyl-propyl)-methanesulfonamide



- 20 A solution of the product of Example 2 (15 mg, 0.04 mmol) in a 1:1 mixture of tetrahydrofuran and dichloromethane (2 mL) containing Hunig's base (9 μ L, 0.05 mmol) was treated with methanesulfonyl chloride (4 μ L, 0.05mmol) and stirred at room temperature for 8 hours. The mixture was diluted with water and extracted with dichloromethane. The aqueous layer was separated and extracted with
- 25 additional dichloromethane, the organic layers were combined, dried over anhydrous magnesium sulphate, filtered and concentrated at reduced pressure. The residue was chromatographed on a Gilson HPLC to give the title compound (8 mg, 44%) as a yellow solid; MS(ES) *m/e*. 451 [M+H]⁺.

Example 5


1,1,1-trifluoro-N-(2-(4-(6-methoxy-naphthalen-2-yl)-5-pyridin-4-yl-1H-imidazol-2-yl)-2-methyl-propyl)-methanesulfonamide



- 5 The title compound (9 mg, 33%) was prepared starting from the product of Example 2 and 1,1,1-trifluoromethanesulfonyl chloride using the method described in Example 4; MS(ES) m/e 505 [M+H]⁺.

Example 6


- 10 2,2,2-trifluoro-N-(2-(4-(6-methoxy-naphthalen-2-yl)-5-pyridin-4-yl-1H-imidazol-2-yl)-2-methyl-propyl)-ethanesulfonamide




- 15 The title compound (12 mg, 43%) was prepared starting from the product of Example 2 and 2,2,2-trifluoroethanesulfonyl chloride using the method described in Example 4; MS(ES) m/e 519 [M+H]⁺.

Example 7

- 20 (2-(4-(6-methoxy-naphthalen-2-yl)-5-pyridin-4-yl-1H-imidazol-2-yl)-2-methyl-propyl)-propanesulfonamide




- 25 The title compound (7 mg, 27%) was prepared starting from the product of Example 2 and propanesulfonyl chloride using the method described in Example 4; MS(ES) m/e 479 [M+H]⁺.

Example 83-Chloro-N-(2-(4-(6-methoxy-naphthalen-2-yl)-5-pyridin-4-yl-1H-imidazol-2-yl)-2-methyl-propyl)-propanesulfonamide


- 5 The title compound (11 mg, 40%) was prepared starting from the product of Example 2 and 3-chloro-propanesulfonyl chloride using the method described in Example 4; MS(ES) m/e 514 [M+H]⁺.

Example 9

- 10 (2-(4-(6-methoxy-naphthalen-2-yl)-5-pyridin-4-yl-1H-imidazol-2-yl)-2-methyl-propyl)-butanesulfonamide



- The title compound (8 mg, 30%) was prepared starting from the product of Example 2 and butanesulfonyl chloride using the method described in Example 4;
15 MS(ES) m/e 493 [M+H]⁺.

Example 101-Ethyl-3-(2-(4-(6-methoxy-naphthalen-2-yl)-5-pyridin-4-yl-1H-imidazol-2-yl)-2-methyl-propyl)-urea


- 20 A solution of the product of Example 2 (20 mg, 0.05 mmol) in dichloromethane (2 mL) containing Hunig's base (10 µL, 0.07 mmol) was treated with ethyl isocyanate (6 µL, 0.07 mmol) and stirred at room temperature for 8 hours. The mixture was diluted with water and extracted with dichloromethane. The
25 aqueous layer was separated and extracted with additional dichloromethane, the organic layers were combined, dried over anhydrous magnesium sulphate, filtered

and concentrated at reduced pressure. The residue was chromatographed on a Gilson HPLC to give the title compound (12 mg, 50%) as a yellow solid; MS(ES) m/e 444 $[M+H]^+$.

5

Example 11

1-(2-Chloroethyl)-3-(2-(4-(6-methoxy-naphthalen-2-yl)-5-pyridin-4-yl)-1*H*-imidazol-2-yl)-2-methyl-propyl)-urea




The title compound (13 mg, 51%) was prepared starting from the product of Example 2 and 3-chloroethyl isocyanate using the method described in Example 10; MS(ES) m/e 478 $[M+H]^+$.

10

Example 12

1-*n*-Propyl-3-(2-(4-(6-methoxy-naphthalen-2-yl)-5-pyridin-4-yl)-1*H*-imidazol-2-yl)-2-methyl-propyl)-urea

15




The title compound (12 mg, 49%) was prepared starting from the product of Example 2 and *n*-propyl isocyanate using the method described in Example 10; MS(ES) m/e 458 $[M+H]^+$.

20

Example 13

1-Isopropyl-3-(2-(4-(6-methoxy-naphthalen-2-yl)-5-pyridin-4-yl)-1*H*-imidazol-2-yl)-2-methyl-propyl)-urea




The title compound (12 mg, 49%) was prepared starting from the product of Example 2 and *n*-propyl isocyanate using the method described in Example 10; MS(ES) *m/e* 458 [M+H]⁺.

5

Example 14

1-*tert*-Butyl-3-(2-(4-(6-methoxy-naphthalen-2-yl)-5-pyridin-4-yl-1*H*-imidazol-2-yl)-2-methyl-propyl)-urea




The title compound (10 mg, 39%) was prepared starting from the product of Example 2 and *tert*-butyl isocyanate using the method described in Example 10; MS(ES) *m/e* 472 [M+H]⁺.

10

Example 15

1-Methylformyl-3-(2-(4-(6-methoxy-naphthalen-2-yl)-5-pyridin-4-yl-1*H*-imidazol-2-yl)-2-methyl-propyl)-urea

15




The title compound (13 mg, 51%) was prepared starting from the product of Example 2 and methylformyl isocyanate using the method described in Example 4; MS(ES) *m/e* 474 [M+H]⁺.

20

Example 16

1-(3,5-Dimethyl-isoxazol-4-yl)-3-(2-(4-(6-methoxy-naphthalen-2-yl)-5-pyridin-4-yl-1*H*-imidazol-2-yl)-2-methyl-propyl)-urea




The title compound (11 mg, 40%) was prepared starting from the product of Example 2 and *tert*-butyl isocyanate using the method described in Example 10; MS(ES) *m/e* 511 [M+H]⁺.

5

Example 17

1-*n*-Propyl-3-(2-(4-(6-methoxy-naphthalen-2-yl)-5-pyridin-4-yl)-1*H*-imidazol-2-yl)-2-methyl-propyl)-thiourea




10

The title compound (7 mg, 28%) was prepared starting from the product of Example 2 and *n*-propyl thioisocyanate using the method described in Example 10; MS(ES) *m/e* 474 [M+H]⁺.

Example 18

15

1-*n*-Butyl-3-(2-(4-(6-methoxy-naphthalen-2-yl)-5-pyridin-4-yl)-1*H*-imidazol-2-yl)-2-methyl-propyl)-thiourea




20

The title compound (8 mg, 31%) was prepared starting from the product of Example 2 and *n*-butyl thioisocyanate using the method described in Example 10; MS(ES) *m/e* 488 [M+H]⁺.

Example 19

1-Isopropyl-3-(2-(4-(6-methoxy-napthalen-2-yl)-5-pyridin-4-yl)-1*H*-imidazol-2-yl)-2-

methyl-propyl)-thiourea




- 5 The title compound (6 mg, 23%) was prepared starting from the product of Example 2 and *sec*-butyl thioisocyanate using the method described in Example 10; MS(ES) *m/e* 488 [M+H]⁺.

Example 20

1-Ethyl-3-(2-(4-(6-methoxy-napthalen-2-yl)-5-pyridin-4-yl)-1*H*-imidazol-2-yl)-2-

10 methyl-propyl)-thiourea




- 15 The title compound (12mg, 49%) was prepared from Example 2 and ethyl thioisocyanate using the method described in Example 10. MS(ES⁺) *m/e* 460 [M+H]⁺.

Example 21

1-Methyl-3-(2-(4-(6-methoxy-napthalen-2-yl)-5-pyridin-4-yl)-1*H*-imidazol-2-yl)-2-


methyl-propyl)-thiourea



- 20 The title compound (8mg, 30%) was prepared from Example 2 and methyl thioisocyanate using the method described in Example 10. MS(ES⁺) *m/e* 446 [M+H]⁺.

Example 22

- 25 1-(2-(4-(6-methoxy-napthalen-2-yl)-5-pyridin-4-yl)-1*H*-imidazol-2-yl)-2-methyl-propyl)- 3-(2-methoxyethyl)-thiourea




The title compound (7mg, 27%) was prepared from Example 2 and 2-methoxyethyl isothiocyanate using the method described in Example 10. MS(ES+) m/e 490 [M+H]⁺.

5

Example 23


1-(2-(4-(6-methoxy-naphthalen-2-yl)-5-pyridin-4-yl)-1H-imidazol-2-yl)-2-methyl-propyl)-3-(2-morpholin-4-yl-ethyl)-thiourea



10 The title compound (10mg, 34%) was prepared from Example 2 and *sec*-butyl thioisocyanate using the method described in Example 10. MS(ES+) m/e 545 [M+H]⁺.

Example 24


15 1-(2-(4-(6-methoxy-naphthalen-2-yl)-5-pyridin-4-yl)-1H-imidazol-2-yl)-2-methyl-propyl)-3-(2-piperidin-4-yl-ethyl)-thiourea



20 The title compound (9mg, 31%) was prepared from Example 2 and *sec*-butyl thioisocyanate using the method described in Example 10. MS(ES+) m/e 543 [M+H]⁺.

Example 25


Cyclohexylmethyl-(2-(4-(6-methoxy-naphthalen-2-yl)-5-pyridin-4-yl)-1H-imidazol-2-yl)-2-methyl-propyl)-amine



A solution of the product of Example 2 (20 mg, 0.05 mmol) in dichloromethane (2 mL) was treated with cyclohexaldehyde (3 mg, 0.07 mmol) and sodium trimethoxyborohydride (9 mg, 0.07 mmol). The solution was stirred at room temperature for 4 hours. The mixture was diluted with water and extracted with ethyl acetate. The aqueous layer was separated and extracted with additional ethyl acetate, the organic layers were combined, dried over anhydrous magnesium sulphate, filtered and concentrated at reduced pressure. The residue was chromatographed on a Gilson HPLC to give the title compound (10 mg, 40%) as a yellow solid; MS(ES) m/e 469 [M+H]⁺.

Example 26


Bis-*n*-butyl-(2-(4-(6-methoxy-naphthalen-2-yl)-5-pyridin-4-yl-1*H*-imidazol-2-yl)-2-methyl-propyl)-amine



The title compound (12 mg, 47%) was prepared starting from the product of Example 2 and butyraldehyde using the method described in Example 25; MS(ES) m/e 485 [M+H]⁺.

Example 27


Bis-cyclohexylmethyl-(2-(4-(6-methoxy-naphthalen-2-yl)-5-pyridin-4-yl-1*H*-imidazol-2-yl)-2-methyl-propyl)-amine



The title compound (4 mg, 13%) was prepared starting from the product of Example 2 and cyclohexylaldehyde using the method described in Example 25; MS(ES) m/e 565 [M+H]⁺.

Example 28

(2-(4-(6-methoxy-naphthalen-2-yl)-5-pyridin-4-yl-1*H*-imidazol-2-yl)-2-methyl-propyl)-(3-methylsulfanyl-propyl)-amine




5

The title compound (4 mg, 16%) was prepared starting from the product of Example 2 and 1-thiomethylpropionaldehyde using the method described in Example 25; MS(ES) m/e 461 [M+H]⁺.

Example 29

(2-(4-(6-methoxy-naphthalen-2-yl)-5-pyridin-4-yl-1*H*-imidazol-2-yl)-2-methyl-propyl)-bis-(3-methylsulfanyl-propyl)-amine




10

15 The title compound (11 mg, 46%) was prepared starting from the product of Example 2 and 1-thiomethylpropionaldehyde using the method described in Example 25; MS(ES) m/e 549 [M+H]⁺.

Example 30

20 Isobutyl-(2-(4-(6-methoxy-naphthalen-2-yl)-5-pyridin-4-yl-1*H*-imidazol-2-yl)-2-methyl-propyl)-(3-methylsulfanyl-propyl)-amine




25

The title compound (11 mg, 48%) was prepared starting from the product of Example 2 and isopropionaldehyde using the method described in Example 25; MS(ES) m/e 429 [M+H]⁺.

Example 31


Bis-isobutyl-(2-(4-(6-methoxy-naphthalen-2-yl)-5-pyridin-4-yl-1*H*-imidazol-2-yl)-2-methyl-propyl)-(3-methylsulfanyl-propyl)-amine



The title compound (11 mg, 42%) was prepared starting from the product of
 5 Example 2 and *i*-propionaldehyde using the method described in Example 25;
 MS(ES) *m/e* 485 [M+H]⁺.

Example 32

(2,2-Dimethylpropyl)-(2-(4-(6-methoxy-naphthalen-2-yl)-5-pyridin-4-yl-1*H*-
 10 imidazol-2-yl)-2-methyl-propyl)-(3-methylsulfanyl-propyl)-amine




The title compound (16 mg, 67%) was prepared starting from the product of
 Example 2 and *t*-butyraldehyde using the method described in Example 25; MS(ES)
 15 *m/e* 443 [M+H]⁺.

All publications, including but not limited to patents and patent applications,
 cited in this specification are herein incorporated by reference as if each individual
 publication were specifically and individually indicated to be incorporated by
 reference herein as though fully set forth.

The above description fully discloses the invention including preferred
 20 embodiments thereof. Modifications and improvements of the embodiments
 specifically disclosed herein are within the scope of the following claims. Without
 further elaboration, it is believed that one skilled in the art can, using the preceding
 description, utilize the present invention to its fullest extent. Therefore, the
 25 Examples herein are to be construed as merely illustrative and not a limitation of the
 scope of the present invention in any way. The embodiments of the invention in
 which an exclusive property or privilege is claimed are defined as follows.

What is Claimed Is:

1. A compound of formula (I):



(I)

wherein

V is CH or N;

Ar is a naphth-2-yl, naphth-1-yl, a bicyclic or tricyclic heteroaromatic ring,
10 which ring may be optionally substituted;

Y is $NR^{10}R^{11}$, $NR^{10}C(Z)NR^{10}R^{11}$, $NR^{10}C(Z)NR^{10}C(Z)OR^{11}$, $NR^{10}COOR^{11}$ or $NR^{10}SO_2R^{11}$;

n is 0, 1, 2, 3 or 4;

X is O, CH_2 , S or NH;

15 Z is oxygen or sulfur;

R^1 is independently hydrogen, $X-R^4$, halogen, hydroxy; optionally substituted C_{1-6} alkyl, optionally substituted C_{1-6} alkylsulfinyl, CH_2OR^5 , amino, mono or di- C_{1-6} alkylamino, $N(R^6)C(O)R^7$, $N(R^6)S(O)_2R^8$, or a 5 to 7-membered N-heterocyclyl ring which optionally contains an additional heteroatom selected from O, S and NR^9 ;

20 R^2 and R^3 independently represent optionally substituted C_{1-6} alkyl, or R^2 and R^3 together with the carbon atom to which they are attached form an optionally substituted C_{3-7} cycloalkyl or C_{3-7} cycloalkenyl ring, or R^2 and R^3 together with the carbon atom to which they are attached form an optionally substituted 5 to 7-membered heterocyclyl ring containing up to 3 heteroatoms
25 selected from N, O and S;

R^4 is independently C_{1-6} alkyl, aryl, aryl C_{1-6} alkyl, heterocyclyl, heterocyclyl C_{1-6} alkyl, heteroaryl, or a heteroaryl C_{1-6} alkyl moiety, and wherein any of these moieties may be optionally substituted;


30 R^5 is hydrogen, $C(Z)R^{12}$ or optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, or $S(O)_2R^8$;

R^6 is hydrogen or C_{1-6} alkyl;

- R⁷ is hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, aryl, arylC₁₋₆alkyl, heteroaryl, heteroarylC₁₋₆alkyl, heterocyclyl, or heterocyclylC₁₋₆alkyl;
R⁸ is C₁₋₆alkyl, C₃₋₇cycloalkyl, aryl, arylC₁₋₆alkyl, heteroaryl, heteroarylC₁₋₆alkyl, heterocyclyl, or heterocyclylC₁₋₆alkyl;
5 R⁹ is hydrogen, C₁₋₄alkyl, C₃₋₇cycloalkyl or aryl;
R¹⁰ and R¹² are independently selected from hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl C₁₋₆alkyl, aryl, arylC₁₋₆alkyl, heterocyclyl, heterocyclylC₁₋₆alkyl, heteroaryl and heteroarylC₁₋₆alkyl, any of which may be optionally substituted; and
10 R¹¹ is hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl C₁₋₆alkyl, aryl, arylC₁₋₆alkyl, heterocyclyl, heterocyclylC₁₋₆alkyl, heteroaryl, or heteroarylC₁₋₆alkyl, any of which may be optionally substituted; or R¹⁰ and R¹¹ may together with the nitrogen may form a 5 to 7 membered ring optionally containing an additional heteroatom selected from O, S, or NR⁹;
15 or a pharmaceutically acceptable salt thereof.
2. The compound according to Claim 1 wherein V is CH.
3. The compound according to Claim 1 wherein V is N.
- 20 4. The compound according to any one of Claims 1 to 3 wherein R¹ is hydrogen, or the moiety X-R⁴.
5. The compound according to Claim 4 wherein X is oxygen or nitrogen.
- 25 6. The compound according to Claim 4 or 5 wherein R⁴ is an optionally substituted alkyl, aryl or arylC₁₋₆alkyl.
7. The compound according to any one of the preceding claims wherein Ar is an optionally substituted naphthyl, benzothiophene or benzofuran ring.
- 30 8. The compound according to claim 7 wherein the Ar ring is substituted by up to 3 substituents independently selected from halo, hydroxy, hydroxy C₁₋₆alkyl, or C₁₋₆alkoxy.
- 35 9. The compound according to claim 8 wherein Ar is a naph-2-yl optionally substituted by a C₁₋₆alkoxy group.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/31791

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : A61K 31/4439, 31/508; C07D 401/04, 403/04 US CL : 514/341, 256; 546/274.1; 544/333 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 514/341, 256; 546/274.1; 544/333		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched NONE		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) STN EXPRESS		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A, P	Database CAPLUS on STN, AN 2000:314693, REVESZ "Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles and their preparation, compositions, and use" Abstract WO 2000026209, 11 May 2000, see entire abstract.	1-6, 10-13, 15-20
A,P -- X,P -- Y,P	Database CAPLUS on STN, AN 1999:764034, "Preparation of pyridinylimidazoles for treatment of CSBP kinase mediated disease" Abstract, WO 9961437, 02 December 1999, see entire abstract.	1-6, 10-13, 15-20
X	WO 99/01449 A1(REVESZ)14 January 1999 (14.01.99), see page 2.	1-6, 10-13, 15-20
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* "A" "E" "L" "O" "P"	Special categories of cited documents document defining the general state of the art which is not considered to be of particular relevance earlier document published on or after the international filing date document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed	"T" "X" "Y" "G" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family
Date of the actual completion of the international search 14 DECEMBER 2000	Date of mailing of the international search report 21 MAR 2001	
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer JANE FAN  Telephone No. (703) 308-0196	